Trailing-twelve-month (TTM) revenue is $254.25 Billion with a year-over-year growth of +14.23%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $64,009,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q2 FY2026Period ended 2025-12-31 | $65,441,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-05 |
| Q3 FY2026Period ended 2026-03-31 | $60,940,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q4 FY2026Period ended 2026-06-30 | $63,858,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $254,248,000,000 |
Current P/S: $55,012,647,340 market capitalization ÷ $254,248,000,000 TTM revenue = 0.22x.
Market capitalization source: FMP quote. Quote observed 2026-09-14T20:00:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $63.86B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-14T23:40:14.970Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Cardinal Health At Home Solutions | $2.2B | $2.4B | $2.6B | N/A | N/A | N/A |
| GMPD | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Non-US | $4.7B | $4.5B | $4.6B | $1.7B | $1.7B | $1.7B |
| UNITED STATES | $157.8B | $176.9B | $200.4B | $225.2B |
$254.25B
$254.25 Billion
+14.23%
vs. $222.58B a year ago (TTM)
+9.37%
5 Year compound annual growth rate
1 Year
+14.23%
3 Year
+7.44%
5 Year
+9.37%
10 Year
+7.66%
15 Year
+6.23%
20 Year
+5.92%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $254.25B | +$31.67B | +14.23% |
| 2025 | $222.58B | ($4.25B) | (1.87%) |
| 2024 | $226.83B | +$21.85B | +10.66% |
| 2023 | $204.98B | +$23.65B | +13.04% |
| 2022 | $181.33B | +$18.86B | +11.61% |
| 2021 |
TTM Growth
+14.23%
3-Year CAGR
+7.44%
5-Year CAGR
+9.37%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-14T23:40:14.970Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $12.4B |
| $12.6B |
| $12.7B |
| Medical Member | $14.5B | $13.5B | $12.4B | N/A | N/A | N/A |
|---|
| Nuclear Precision Health Services | $808M | $911M | $1.2B | N/A | N/A | N/A |
|---|
| Other Operating Segment | N/A | N/A | N/A | $4.5B | $5.4B | $6.8B |
|---|
| Pharmaceutical Member | $145.0B | $164.6B | $188.8B | $210.0B | $204.6B | $234.8B |
|---|
| $252.6B |
| $162.47B |
| +$9.54B |
| +6.24% |
| 2020 | $152.92B | +$7.39B | +5.08% |
| 2019 | $145.53B | +$8.72B | +6.38% |
| 2018 | $136.81B | +$6.83B | +5.26% |
| 2017 | $129.98B | +$8.43B | +6.94% |
